Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 14;12(8):1161. doi: 10.3390/cells12081161

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

OTUD5 is aberrantly expressed in several types of tumors. (A) By analyzing the data in the TCGA database, we found that OTUD5 expression was significantly lower in glioblastoma (GBM), kidney chromophobe (KICH) and uterine corpus endometrial carcinoma (UCEC) and significantly highly expressed in breast cancer (BRCA), bile duct cancer (CHOL), colon cancer (COAD), esophageal cancer (ESCA), head and neck cancer (HNSC), liver cancer (LIHC), lung adenocarcinoma (LUAD), rectal cancer (READ) and stomach cancer (STAD). Data were analyzed using TIMER2.0. p < 0.05 *, p < 0.01 **, p < 0.001 ***. (B) The overall survival (OS) of OTUD5 in esophageal cancer (ESCA). (C) The recurrence-free survival (RFS) of OTUD5 in esophageal cancer (ESCA). High mRNA expression of OTUD5 was significantly associated with poor OS and RFS in ESCA. (D,E) The OS and progression-free survival (PFS) of OTUD5 in stomach cancer (STAD). High mRNA expression of OTUD5 was significantly associated with OS and PFS in STAD. (B–E) Data were analyzed using the Kaplan–Meier Plotter, a web-based survival analysis tool.